ReviewCurrent cardiology reports2022
Closed-Loop Artificial Pancreas Therapy for Type 1 Diabetes.
Review in Current cardiology reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 18 citations in OpenAlex.
- Artificial Intelligence-Based Wearable Sensing Technologies for the Management of Cancer, Diabetes, and COVID-19.Biosensors · 2025Review
- Changes in 90-Day Time in Range Among Youth With Type 1 Diabetes Initiating Different Automated Insulin Delivery Systems.The Journal of clinical endocrinology and metabolism · 2025Article
- Understanding Device Integrations Within Diabetes Apps: Mixed Methods Analysis of App Features and User Reviews.JMIR diabetes · 2025Article
- [Research progress on automated insulin delivery system in the field of diabetes management].Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi · 2024Review
- Recent advances in the precision control strategy of artificial pancreas.Medical & biological engineering & computing · 2024Review
- Beyond A1C: exploring continuous glucose monitoring metrics in managing diabetes.Endocrine connections · 2023Review
- Case of an 89-year-old patient with type 1 diabetes whose indices of continuous glucose monitoring were significantly improved using an insulin pump with a hybrid closed-loop mode.Geriatrics & gerontology international · 2023Article
- Advances in insulin therapy from discovery to β-cell replacement.Journal of diabetes investigation · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewClosed-loop insulin pump systems (artificial pancreas) represent the cutting edge of insulin delivery technology. There are only a few systems currently approved for use in the USA: the MiniMed 670G/770G (which share an algorithm), t:slim X2 Control IQ, and the Omnipod 5. We review these systems and look into the future of the technology. RECENT
findingsAll of the approved closed-loop insulin pump systems have demonstrated in multicenter prospective trials improvements in time in range, hemoglobin A1c, and time spent in hypoglycemia. The newer systems have also improved time spent in automation. Comparisons between the systems with regard to glycemic control are difficult to make due to differences in clinical trial design, but there are notable differences in the user experience between systems. The past few years have been a time of exponential development in the field of closed-loop insulin pump systems. However, more research is needed to provide full automation of these systems without any need for information from the user.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.